- Reports: ESI may start 'price war' over new hepatitis C drugs
- Bristol-Myers Squibb sells off diabetes business
- Newly approved hepatitis C treatment by Gilead Sciences said to offer major advance in treatment
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
SEATTLE Bristol-Myers Squibb will acquire Seattle-based biotech ZymoGenetics, Bristol said Wednesday.
The New York-based drug maker will acquire ZymoGenetics for $885 million, or $9.75 per share. The boards of both companies approved the deal unanimously.
The buyout gives Bristol ownership of Recothrom, used to control bleeding during surgical procedures, pegylated-interferon lambda, an investigational treatment for hepatitis C in mid-stage clinical trials, and IL-21, a treatment for melanoma also in mid-stage trials.
“The acquisition of ZymoGenetics brings us full ownership of a promising investigational biologic that strengthens our very diversified hepatitis C portfolio,” Bristol CEO Lamberto Andreotti said. “Building on our leadership in virology, we are developing a strong portfolio to help patients with hepatitis C.”